AVE 7688

03/01/2009 - "In this study, we determined the effect of treating Zucker diabetic fatty (ZDF) rats, an animal model of type 2 diabetes, with AVE7688 on vascular and neural function. "
10/15/2011 - "In this study we sought to determine the effect of Ilepatril treatment of high fat fed/low dose streptozotocin-diabetic rats, a model for type 2 diabetes, on vascular and neural complications. "
02/29/2012 - "Treating high fat fed/low dose streptozotocin-diabetic rats; model of type 2 diabetes, with ilepatril (vasopeptidase inhibitor, blocks neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE)) improved vascular and neural functions. "
08/01/2005 - "We evaluated the effect of ramipril (a pure ACE inhibitor) and AVE7688 (a dual inhibitor of ACE and neutral endopeptidase) on renal accumulation of the advanced glycation end-product (AGE) 3-deoxyglucosone-imidazolone, carboxymethyllysine (CML) and pentosidine, and on clearance of CML in type 2 diabetes. "

03/01/2008 - "Ilepatril is currently in phase IIb/III clinical trials for hypertension and phase II trials for diabetic nephropathy. "
01/01/2004 - "The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy."
03/01/2008 - "sanofi-aventis (formerly Aventis Pharma AG) is developing ilepatril (AVE-7688), a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, for the potential treatment of hypertension and diabetic nephropathy. "
01/01/2004 - "We tested the effects of the dual inhibition of both angiotensin converting enzyme and neutral endopeptidase by the vasopeptidase inhibitor AVE7688 in an animal model of Type 2 diabetic nephropathy. "

01/01/2004 - "AVE7688 ameliorates proteinuria in Zucker diabetic fatty rats with established diabetes mellitus. "
11/01/2004 - "Enalapril achieved a 47% reduction in proteinuria (277 +/- 81 mg/day, P < 0.01 vs. vehicle) to levels that remained higher (P < 0.01), however, than those after AVE7688. "
09/01/2004 - "In the AVE7688 plus icatibant group, proteinuria was significantly higher than in the AVE7688 only group (2.0+/-0.6 mg kg(-1) h(-1)), but still reduced compared to placebo. "
08/01/2005 - "AVE7688 decreased proteinuria from 12 +/- 3 g/L in untreated mice to 2 +/- 1 g/L (early) and to 4 +/- 1 g/L (late therapy, P < 0.05), as well as serum-urea from 247 +/- 27 to 57 +/- 10 and to 105 +/- 20 mmol/L (P < 0.05). "
11/01/2006 - "At week 17 after sequential induction of unilateral nephrectomy and myocardial infarction, treatment with lisinopril (ACEi), AVE7688 (VPI), or vehicle was initiated for 6 wk. Proteinuria and systolic BP (SBP) were evaluated weekly. "

01/01/2015 - "Both ilepatril and olmesartan conferred strong cardiorenal protective effects in rats with renal failure. "

01/01/2011 - "Rats fed a high fat diet containing AVE7688 did not become obese and vascular and sensory nerve dysfunction and impaired glucose tolerance were improved. "